ESR1 and breast cancer: A clinical study conducted by investigators at the Memorial Sloan Kettering Cancer Center (NCT00468715/TBCRC011) showed that daily treatment with 150 mg bicalutamide led to 19% CBR lasting longer than 6 months and a median progression-free survival (PFS) of 12 weeks in ER-negative/PR-negative/AR-positive metastatic BC patients [6].